Viking Therapeutics’ weight-loss tablet shows promise in small study
Viking Therapeutics’ (VKTX.O) experimental tablet reduced weight by as much as 3.3% when tested in volunteers enrolled in a small early-stage trial, meeting Wall Street expectations and sending the company’s shares up 15% in premarket trading on Tuesday.